glp-1 and dementia Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline in Diabetes Mellitus What's Next for Alzheimer's Treatment?

Nonequivalence of the two subunits of horse erythrocyte glutathione transferase in their reaction with sulfhydryl reagents

Molybdenum is indispensable for enzymes that detoxify sulfur compounds

Focusing only on the scale rather than labs and body composition

When brand-name Ozempic and Wegovy were unavailable, the FDA allowed compounding pharmacies to produce semaglutide

By DEE-ANN DURBIN AP Business Writer Meals and snacks with GLP-1 Friendly labels on the packaging are becoming more common in U.S

Cignas 2026 commercial PA criteria for Wegovy require five elements: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity